M3VAS Validation in Polish Population
The Maudsley 3-item Visual Analogue Scale (M3VAS) Validation in Polish Population Diagnosed With Major Depressive Episode
1 other identifier
observational
150
1 country
1
Brief Summary
Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD). Nevertheless, there is currently no standardized visual analogue scale available to assess the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS) is a newly developed tool for participants to self-assess core symptoms of depression: mood quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a primary symptom, it is included due to its critical relevance to safety. Participants will be instructed to rate the intensity and frequency of their experiences over the preceding two weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value based on the mark's position, utilizing the left edge as 0 and the right as 100. The total score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The M3VAS exhibited good psychometric properties in British population. In this study, the objective is to assess the psychometric properties of the scale within the Polish population diagnosed with major depressive episode within major depressive disorder or bipolar disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 9, 2024
CompletedStudy Start
First participant enrolled
May 9, 2024
CompletedFirst Posted
Study publicly available on registry
May 14, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
May 14, 2024
May 1, 2024
2.3 years
May 9, 2024
May 9, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Maudsley 3-item Visual Analogue Scale (M3VAS)
To analyze internal consistency and factor analysis
Baseline
Secondary Outcomes (1)
16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)
Baseline
Study Arms (1)
Major Depressive Episode
Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Major Depressive Disorder (MDD) or Bipolar Disorder (BD), as determined by a psychiatrist.
Interventions
Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
Eligibility Criteria
Inpatients referred to the tertiary-reference unit for mood disorders with MDD or BD diagnosis, currently either with current depression or euthymic
You may qualify if:
- Diagnosis as provided by DSM-5 criteria:
- Major depressive disorder (MDD) Bipolar disorder (BD)
You may not qualify if:
- Diagnosis as provided by DSM-5 criteria:
- Psychotic disorders Current Mania or hypomania within bipolar disorder (BD)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Medical University of Gdansklead
- King's College Londoncollaborator
Study Sites (1)
Medical University of Gdańsk
Gdansk, Poland
Related Publications (1)
Moulton CD, Strawbridge R, Tsapekos D, Oprea E, Carter B, Hayes C, Cleare AJ, Marwood L, Mantingh T, Young AH. The Maudsley 3-item Visual Analogue Scale (M3VAS): Validation of a scale measuring core symptoms of depression. J Affect Disord. 2021 Mar 1;282:280-283. doi: 10.1016/j.jad.2020.12.185. Epub 2020 Dec 31.
PMID: 33418379BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2024
First Posted
May 14, 2024
Study Start
May 9, 2024
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
September 1, 2026
Last Updated
May 14, 2024
Record last verified: 2024-05